Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna, Pfizer, and Other Vaccine Stocks Dropped Today

By Joe Tenebruso – Sep 13, 2021 at 5:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Booster shot revenue could be at risk.

What happened

Shares of COVID-19 vaccine makers fell on Monday after a scientific review concluded that the general population does not require booster shots. 

By the close of trading, shares of Moderna (MRNA 0.48%), BioNTech (BNTX 0.16%), Novavax (NVAX -1.96%), and Pfizer (PFE -0.33%) were down 6.6%, 6.3%, 3.5%, and 2.2%, respectively.

So what

In an article published in the peer-reviewed medical journal The Lancet, a group of respected scientists from around the world said that existing COVID-19 vaccines remain "protective against severe disease from all the main viral variants." 

They went on to say that, although the ability of vaccines made by the likes of Moderna and Pfizer to prevent infection is somewhat less for the troublesome delta variant than it is for the original strain, "there is still high vaccine efficacy against both symptomatic and severe disease due to the delta variant."

"Current evidence does not, therefore, appear to show a need for boosting in the general population," the scientists said.

A healthcare professional is administering a vaccine to a patient.

Image source: Getty Images.

In turn, the scientists contend that current stockpiles of COVID-19 vaccines "could save more lives" if they are administered to unvaccinated individuals in countries with low vaccination rates, rather than used for booster shots. The group also noted that increasing vaccination rates could help to reduce the opportunity for the virus to mutate.

"Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated," the group said. "If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants."

Now what 

Investors have come to view booster shots as a potential source of valuable, recurring revenue for the major vaccine makers. However, if booster shots are shown to be unnecessary for the majority of the population, shareholders might need to readjust their profit forecasts.

Still, investors should note that, as of today, the Biden administration intends to move forward with its booster program beginning this fall. White House press secretary Jen Psaki said last week the U.S. can provide booster shots to Americans while also donating vaccines to countries in need. 

"Our view is that this is a false choice," Psaki said. "And the United States has donated and shared about 140 million doses with over 90 countries -- more than all other countries combined."

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Stocks Mentioned

Pfizer Stock Quote
$50.91 (-0.33%) $0.17
Novavax Stock Quote
$16.52 (-1.96%) $0.33
Moderna Stock Quote
$182.35 (0.48%) $0.87
BioNTech Se Stock Quote
BioNTech Se
$169.74 (0.16%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.